Histone deacetylase inhibitors as novel anticancer therapeutics.

Abstract

Histone deacetylase inhibitors represent a promising new class of compounds for the treatment of cancer. Inhibitors of this kind currently under clinical evaluation mainly target the classical (Rpd3/Hda1) family of histone deacetylases. Of particular note, the U.S. Food and Drug Administration recently approved the first histone deacetylase inhibitor (Zolinza: Merck and Co., Whitehouse Station, NJ, U.S.A.) for the treatment of cutaneous T-cell lymphoma. Dozens of such inhibitors are now in phase ii-iii clinical trials, sometimes in combination with other chemotherapy drugs, for diverse cancer types, including both hematologic and solid tumours. In this mini-review, we provide an overview of the histone deacetylase superfamily, highlight the positive results of deacetylase inhibitors in cancer clinical trials, and comment on the prospects for the next generation of such inhibitors.

• Authors: D R Walkinshaw, X J Yang
• Journal: Current oncology (Toronto, Ont.) (Curr Oncol) Vol. 15 Issue 5 Pg. 237-43 (Oct 2008) ISSN: 1198-0052 [Print] Switzerland
• PMID: 19008999 (Publication Type: Journal Article)